|
Age, years a
|
42.4 (±9.7)
|
43.4 (±9.7)
|
44.2 (±9.31)
|
0.53
|
|
Gender b
| | | |
0.64
|
|
Male
|
369 (56)
|
61 (53)
|
65 (57)
| |
|
female
|
285(44)
|
54 (47)
|
49(43)
| |
|
Height, cm c
|
173 (167–180)
|
173 (168–180)
|
173 (167–180)
|
0.76
|
|
Weight, kg c
|
75.6 (64–84)
|
74.8 (64–83)
|
74.6 (65–84)
|
0.45
|
|
BMI a
|
25.1(±4.00)
|
25.1 (±4.23)
|
25.4 (±4.44)
|
0.52
|
|
Civil status b
| | | |
0.47
|
|
single
|
218 (33)
|
36 (31)
|
35 (31)
| |
|
married
|
330 (51)
|
57 (50)
|
61 (53)
| |
|
divorced
|
95 (14)
|
19 (16)
|
18(16)
| |
|
widowed
|
11 (2)
|
3 (3)
|
0 (0)
| |
|
Education b
| | | |
0.56
|
|
University
|
141 (22)
|
35 (31)
|
28 (25)
| |
|
Apprenticeship
|
466 (72)
|
73 (64)
|
77 (68)
| |
|
Basic education
|
41 (6)
|
6 (5)
|
8 (7)
| |
|
Comorbidities b
| | | | |
|
Arterial hypertension
|
37 (6)
|
9 (8)
|
13 (7)
|
1.00
|
|
Coronary heart disease
|
28 (4)
|
11 (10)
|
2 (2)
|
0.02
|
|
Diabetes mellitus
|
16 (2)
|
12 (11)
|
13 (11)
|
1.00
|
|
Malignancy
|
27 (4)
|
5 (4)
|
4 (4)
|
1.00
|
|
Epilepsy
|
15 (2)
|
5 (4)
|
2 (2)
|
0.45
|
|
Psychiatric disorder
|
91 (14)
|
24 (21)
|
13 (11)
|
0.08
|
|
Antidepressant medication
|
112 (17)
|
23 (20)
|
16 (14)
|
0.31
|
|
Satisfaction with Life Scale (Qol), points c
|
26 (24–30)
|
27 (25–31)
|
26 (23–30)
|
0.82
|
|
Respiratory symptoms b
| | | | |
|
Cough
|
253 (39)
|
34 (30)
|
38 (34)
|
0.61
|
|
Sputum
|
176 (27)
|
25 (22)
|
26 (23)
|
0.97
|
|
Wheezing
|
124 (19)
|
26 (23)
|
17 (15)
|
0.19
|
|
Breathlessness at rest
|
44 (7)
|
12 (10)
|
10 (9)
|
0.84
|
|
Breathlessness on exertion
|
288 (44)
|
47 (41)
|
45 (39)
|
0.94
|
|
Smoking-related history
| | | | |
|
Age at starting smoking, years a
|
17 (±3.7)
|
17 (±3.8)
|
17 (±3.5)
|
1.00
|
|
Prior attempts to quit a
|
3.0 (±3.5)
|
2.9 (±3.3)
|
3.1 (±3.8)
|
0.78
|
|
Duration longest nicotine abstinence, months a
|
20 (±51)
|
21 (±45)
|
20 (±54)
|
0.69
|
|
Years, smoked a
|
22 (±8.5)
|
21 (±10.3)
|
22 (±8.5)
|
0.85
|
|
Number of cigarettes/day b
| | | |
0.29
|
|
0-10
|
82 (13)
|
22 (19)
|
12 (11)
| |
|
11-20
|
329 (50)
|
59 (51)
|
67 (59)
| |
|
21-30
|
184 (28)
|
28 (24)
|
27 (24)
| |
|
>30
|
58 (9)
|
6 (5)
|
8 (7)
| |
|
FTND, points a
|
4.5 (±2.40)
|
3.7 (±2.40)
|
4.5 (±2.30)
|
0.02
|
|
Intensity of craving, (VAS 0–100) a
|
57 (±32)
|
58 (±32)
|
55 (±21)
|
0.09
|
|
Exhaled CO, ppm a
|
22.6 (±14.7)
|
20.2 (±15.1)
|
22.0 (±13.9)
|
0.38
|
|
Pharmacological support
| | | |
0.91
|
|
NRT
| | | | |
|
Mono
|
82 (13)
|
12 (10)
|
11 (10)
| |
|
Combined
|
124 (19)
|
24 (22)
|
21 (19)
| |
|
Mono + Bupropion
|
92 (14)
|
12 (10)
|
13 (12)
| |
|
Combined + Bupropion
|
265 (42)
|
52 (45)
|
57 (50)
| |
|
Bupropion
|
42 (6)
|
5 (4)
|
5 (4)
| |
|
Counselling only
|
47 (6)
|
10 (9)
|
6 (5)
| |
